Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA

Zhong, Wen‐Zhao; Ahluwalia, Sharon K.; Newman, Bryan; Dhapare, Sneha; Zhao, Liang; Luke, Markham C.

doi:10.1007/s43441-021-00372-y

Cited by 6 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When Wixela Inhub (fluticasone propionate and salmeterol xinafoate) Inhalation Powder, the first approved generic for Advair Diskus, 36 entered the market in 2019, the cost savings over the first year reached 941 million dollars with an average 66% reduction in unit cost ($115 for Wixela Inhub vs $334 for Advair Diskus). 37 Generic product cost savings generally are not fully realized until three or four generic versions of a drug-device combination product enter the market. 38 The cost savings associated with generic substitution are appealing to patients but do not eliminate concerns that may arise when a patient unexpectedly receives a generic inhaler that has user interface design differences compared to the brand inhaler.…”

Section: Discussionmentioning

confidence: 99%

Patient Perceptions of Switching to a Generic Dry Powder Inhaler – Increased Understanding Through Journey Mapping

Boudewyns¹,

Davis²,

Tzeng³

et al. 2022

COPD

View full text Add to dashboard Cite

Purpose This qualitative study explored patients’ attitudes about and perceptions of generic dry powder inhaler (DPI) substitution for the brand product and patients’ views of generic product quality, efficacy, design, and usability. Methods Forty COPD and asthma patients (36 adults, four adolescents), who were actively using a brand DPI product, participated in one of six focus groups. Participants completed a journey mapping exercise to assess attitudes and opinions about a scenario where they refill their prescription and unexpectedly receive a generic DPI instead of their brand DPI. The focus groups were audio recorded, transcribed, and analyzed thematically. Results The hypothetical scenario of unexpectedly receiving a generic DPI elicited mixed feelings including: happiness and relief about potential cost savings, confusion, disappointment, anger, and/or frustration with the unexpected switch. Participants in most groups anticipated anxiety or hesitation in using the generic DPI due to concerns about potential differences in usability, uncertainty about correct use, and questions about efficacy. Participants across all groups said they would ask a pharmacist or healthcare provider for information or answers to their questions, and some participants said they would use online resources. When participants held the brand and generic DPI devices, most preferred the brand DPI device and found it easier, less cumbersome, or more convenient to use (due to size and weight). However, many participants reiterated that the potential reduced cost of the generic DPI would be a primary factor in their decision-making related to generic DPI substitution for their brand DPI. Conclusion Patients experienced a mixture of positive and negative feelings when faced with an unexpected generic DPI substitution. Some patients have doubts about their ability to successfully navigate differences in generic device design, and most expressed the desire to participate in discussions and decision-making with their HCP about generic DPI sameness and substitution.

show abstract

Section: Discussionmentioning

confidence: 99%

Patient Perceptions of Switching to a Generic Dry Powder Inhaler – Increased Understanding Through Journey Mapping

Boudewyns¹,

Davis²,

Tzeng³

et al. 2022

COPD

View full text Add to dashboard Cite

show abstract

“…These digital technologies present a new challenge for generic DPI development given the uncertainty with degree to which a generic DPI will be required to include digital technologies, or record and/or communicate this information to the patient, in order to match the RLD DPI. With that said, generic competition with these DPIs is expected to lead to reduced costs for the patient, which has been reported following the introduction of the first Advair Diskus generic [121].…”

Section: Advancements In Dpi Device Technologiesmentioning

confidence: 99%

Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development

et al. 2022

Self Cite

View full text Add to dashboard Cite

Dry powder inhalers (DPIs) are drug–device combination products where the complexity of the formulation, its interaction with the device, and input from users play important roles in the drug delivery. As the landscape of DPI products advances with new powder formulations and novel device designs, understanding how these advancements impact performance can aid in developing generics that are therapeutically equivalent to the reference listed drug (RLD) products. This review details the current understanding of the formulation and device related principles driving DPI performance, past and present research efforts to characterize these performance factors, and the implications that advances in formulation and device design may present for evaluating bioequivalence (BE) for generic development.

show abstract

Assessing prescriber adherence with Global Initiative for Asthma (GINA) guideline-recommended reliever therapy

Tchen,

Vu,

Fleischman

et al. 2023

Intern Emerg Med

View full text Add to dashboard Cite

Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA

Cited by 6 publications

References 27 publications

Patient Perceptions of Switching to a Generic Dry Powder Inhaler – Increased Understanding Through Journey Mapping

Patient Perceptions of Switching to a Generic Dry Powder Inhaler – Increased Understanding Through Journey Mapping

Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development

Assessing prescriber adherence with Global Initiative for Asthma (GINA) guideline-recommended reliever therapy

Contact Info

Product

Resources

About